CoChat

Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: safety, efficacy, biomarker, and pharmacokinetics – CheckMate 908

Open access

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Therapeutic options are limited in pediatric CNS malignancies. CheckMate 908 (NCT03130959) is an open-label, sequential-arm, phase 1b/2 study investigating nivolumab (NIVO) and NIVO + ipilimumab (IPI) in pediatric patients with high-grade CNS malignancies. METHODS: Patients (N = 166) in 5 cohorts received NIVO 3 mg/kg every 2 weeks (Q2W) or NIVO 3 mg/kg + IPI 1 mg/kg every 3 weeks (4 doses) followed by NIVO 3 mg/kg Q2W. Primary endpoints included overall survival (OS; newly diagnosed diffuse intrinsic pontine glioma [DIPG]) and progression-free survival (PFS; other recurrent/progressive or relapsed/resistant CNS cohorts). Secondary endpoints included other efficacy metrics and safety. Exploratory endpoints included pharmacokinetics and biomarker analyses. RESULTS: As of January 13, 2021, median OS (80% CI) was 11.7 (10.3-16.5) and 10.8 (9.1-15.8) months with NIVO and NIVO + IPI, respectively, in newly diagnosed DIPG. Median PFS (80% CI) with NIVO and NIVO + IPI was 1.7 (1.4-2.7) and 1.3 (1.2-1.5) months, respectively, in recurrent/progressive high-grade glioma; 1.4 (1.2-1.4) and 2.8 (1.5-4.5) months in relapsed/resistant medulloblastoma; and 1.4 (1.4-2.6) and 4.6 (1.4-5.4) months in relapsed/resistant ependymoma. In patients with other recurrent/progressive CNS tumors, median PFS (95% CI) was 1.2 (1.1-1.3) and 1.6 (1.3-3.5) months, respectively. Grade 3/4 treatment-related adverse-event rates were 14.1% (NIVO) and 27.2% (NIVO + IPI). NIVO and IPI first-dose trough concentrations were lower in youngest and lowest-weight patients. Baseline tumor programmed death ligand 1 expression was not associated with survival. CONCLUSIONS: NIVO ± IPI did not demonstrate clinical benefit relative to historical data. The overall safety profiles were manageable with no new safety signals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/noad031

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Overall survival. Number of events, median OS, and Kaplan–Meier curve for OS in cohort 1 (newly diagnosed DIPG) (A), cohort 2 (recurrent/progressive HGG) (B), cohort 3 (relapsed/resistant medulloblastoma) (C), cohort 4 (relapsed/resistant ependymoma) (D), and cohort 5 (other recurrent/progressive high-grade CNS tumors) (E). Symbols indicate censored observations. Overlay of Module A and Module B is not intended to provide statistical comparison between the treatment modules. DIPG, diffuse intrinsic pontine glioma; HGG, high-grade glioma; IPI, ipilimumab; NA, not available; NIVO, nivolumab; OS, overall survival.
Figure 1. Overall survival. Number of events, median OS, and Kaplan–Meier curve for OS in cohort 1 (newly diagnosed DIPG) (A), cohort 2 (recurrent/progressive HGG) (B), cohort 3 (relapsed/resistant medulloblastoma) (C), cohort 4 (relapsed/resistant ependymoma) (D), and cohort 5 (other recurrent/progressive high-grade CNS tumors) (E). Symbols indicate censored observations. Overlay of Module A and Module B is not intended to provide statistical comparison between the treatment modules. DIPG, diffuse intrinsic pontine glioma; HGG, high-grade glioma; IPI, ipilimumab; NA, not available; NIVO, nivolumab; OS, overall survival.CC BY-NC · PubMed Central
Figure 2. Progression-free survival. Number of events, median PFS, and Kaplan–Meier curve for PFS per investigator in cohort 1 (newly diagnosed DIPG), cohort 2 (recurrent/progressive HGG) (B), cohort 3 (relapsed/resistant medulloblastoma) (C), cohort 4 (relapsed/resistant ependymoma) (D), and cohort 5 (other recurrent/progressive high-grade CNS tumors) (E). Symbols indicate censored observations. Overlay of Module A and Module B is not intended to provide statistical comparison between the treatment modules. DIPG, diffuse intrinsic pontine glioma; HGG, high-grade glioma; IPI, ipilimumab; NIVO, nivolumab; PFS, progression-free survival.
Figure 2. Progression-free survival. Number of events, median PFS, and Kaplan–Meier curve for PFS per investigator in cohort 1 (newly diagnosed DIPG), cohort 2 (recurrent/progressive HGG) (B), cohort 3 (relapsed/resistant medulloblastoma) (C), cohort 4 (relapsed/resistant ependymoma) (D), and cohort 5 (other recurrent/progressive high-grade CNS tumors) (E). Symbols indicate censored observations. Overlay of Module A and Module B is not intended to provide statistical comparison between the treatment modules. DIPG, diffuse intrinsic pontine glioma; HGG, high-grade glioma; IPI, ipilimumab; NIVO, nivolumab; PFS, progression-free survival.CC BY-NC · PubMed Central
Figure 3. Nivolumab and ipilimumab exposures by age and weight. Observed NIVO and IPI trough (Cmin1) concentrations after first dose by patient age and weight. GM, geometric mean; IPI, ipilimumab; NIVO, nivolumab.
Figure 3. Nivolumab and ipilimumab exposures by age and weight. Observed NIVO and IPI trough (Cmin1) concentrations after first dose by patient age and weight. GM, geometric mean; IPI, ipilimumab; NIVO, nivolumab.CC BY-NC · PubMed Central
Figure 4. Survival in prespecified patient subgroups defined by baseline PD-L1 expression. Forest plots of unstratified HRs for progression per investigator (A) and overall survival (B) based on baseline PD-L1 expression. HR, hazard ratio; mOS, median overall survival; mPFS, median progression-free survival; NA, not applicable; PD-L1, programmed death ligand 1.
Figure 4. Survival in prespecified patient subgroups defined by baseline PD-L1 expression. Forest plots of unstratified HRs for progression per investigator (A) and overall survival (B) based on baseline PD-L1 expression. HR, hazard ratio; mOS, median overall survival; mPFS, median progression-free survival; NA, not applicable; PD-L1, programmed death ligand 1.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Yervoy (ipilimumab), 2021, Prescribing Information

Cited by

See all 73

Metadata

Authors
Dunkel, I. J., Doz, F., Foreman, N. K., Hargrave, D., Lassaletta, A., André, N., Hansford, J. R., Hassall, T., Eyrich, M., Gururangan, S., Bartels, U., Gajjar, A., Howell, L., Warad, D., Pacius, M., Tam, R., Wang, Y., Zhu, L., & Cohen, K.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Université Paris Cité (FR)
  • Morgan Adams Foundation (US)
  • Great Ormond Street Hospital (GB)
  • Department of Pediatric Hematology-Oncology, Hospital Infantil Universitario Niño Jesús , Madrid , Spain
  • Département de Radiothérapie, Hopital pour Enfants de la Timone, Department of Pediatric Hematology and Oncology, AP-HM and Centre de Recherche en Cancérologie de Marseille, Aix Marseille Université , Marseille , France
  • Royal Children's Hospital (AU)
  • Children's Health Queensland Hospital and Health Service (AU)
  • Universitätsklinikum Würzburg (DE)
  • University of Florida (US)
  • Hospital for Sick Children (CA)
  • St. Jude Children's Research Hospital (US)
  • Alder Hey Children's Hospital (GB)
  • Bristol-Myers Squibb (United States) (US)
  • Johns Hopkins University (US)
Corresponding author
Dunkel, Ira J
Venue
Neuro-Oncology
Published
2023-02-20
Volume
25
Issue
8
Pages
1530-1545
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W4321372568
Cited by
73
References
49
Citations by year
2026: 24 · 2025: 26 · 2024: 16 · 2023: 6
FWCI
12.42
Type
journal article
Language
en
Open access
Locations
  • Neuro-Oncology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion, cc-by-nc)
Funders
  • National Institutes of Health
  • National Cancer Institute (P30 CA008748)
  • National Institute for Health and Care Research Great Ormond Street Hospital Biomedical Research Centre
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
nivolumab, ipilimumab, immune checkpoint inhibitors, pediatric central nervous system tumors, diffuse intrinsic pontine glioma, medulloblastoma, ependymoma, recurrent high-grade glioma, overall survival, progression-free survival, treatment-related adverse events, pharmacokinetics, biomarkers, immune-related adverse events, sequential immunotherapy, PD-1/PD-L1 blockade, CTLA-4 blockade, brain tumor immunotherapy
MeSH terms
Ipilimumab, Nivolumab, Antineoplastic Combined Chemotherapy Protocols, Child, Humans, Neoplasms, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.